TP53 and cancer: Soragni et al. (2016) showed that a cell-penetrating peptide (CPP) derived from DNA binding domain of p53, ReACp53, inhibits mutp53 aggregation and rescues WT-like p53 functions in high-grade serous ovarian carcinomas. The concept of using targeted protein degradation (TPD) to treat cancers with mutp53 is also being explored (Dale et al., 2021). Isobe et al. (2020) identified a small molecule, asukamycin, that serves as a “molecular glue” linking mutp53 with E3 ubiquitin ligase UBR7.